IDH1 and cholangiocarcinoma: In a phase III randomized trial, ivosidenib significantly improved PFS (2.7 vs. 1.4 months) and OS (10.3 vs. 7.5 months) compared with placebo in patients with previously treated, locally advanced, or metastatic IDH1-mutant CCA [43].